Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Terry K.W. Ma"'
Publikováno v:
British Journal of Clinical Pharmacology. 72:697-706
Clopidogrel is a pro-drug which is converted to an active metabolite that selectively blocks ADP-dependent platelet activation and aggregation. The main enzyme responsible for activating clopidogrel is the cytochrome P450 (CYP) isoenzyme CYP2C19, whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e28424786085e4f3ed312452d569f04
https://doi.org/10.1111/j.1365-2125.2011.03949.x
https://doi.org/10.1111/j.1365-2125.2011.03949.x
Publikováno v:
International Journal of Cardiology. 150:4-11
Atrial fibrillation (AF) is associated with a fivefold increased risk for stroke due to thromboembolic events. Warfarin remains the standard medical therapy for decades in these patients but is difficult to use safely and conveniently. Chronic warfar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11c6124d415e9843d0b7737d45c146fc
https://doi.org/10.1016/j.ijcard.2010.10.017
https://doi.org/10.1016/j.ijcard.2010.10.017
Publikováno v:
British Journal of Pharmacology. 160:1273-1292
Activation of the renin–angiotensin–aldosterone system (RAAS) results in vasoconstriction, muscular (vascular and cardiac) hypertrophy and fibrosis. Established arterial stiffness and cardiac dysfunction are key factors contributing to subsequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbedbd7627b1e3afcf34b50294bdf959
https://doi.org/10.1111/j.1476-5381.2010.00750.x
https://doi.org/10.1111/j.1476-5381.2010.00750.x
Publikováno v:
Pharmacology & Therapeutics. 125:249-259
Dual antiplatelet therapy with aspirin and clopidogrel has been shown to reduce subsequent cardiac events in patients with acute coronary syndrome or coronary artery stenting. Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b609a746470737e8de77746b2063f7d
https://doi.org/10.1016/j.pharmthera.2009.10.008
https://doi.org/10.1016/j.pharmthera.2009.10.008
Publikováno v:
Pharmacologytherapeutics. 129(2)
For many years, warfarin was the only effective oral anticoagulant to prevent and treat thromboembolism. Nevertheless, its clinical use is limited by a narrow therapeutic window, extensive drug interactions, need of strict dietary control and frequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1be5e24db7857bd26bb4b56c84d3a617
https://pubmed.ncbi.nlm.nih.gov/20920530
https://pubmed.ncbi.nlm.nih.gov/20920530